Inmode Ltd


Inmode Ltd

Health CareHealth Care Equipment & Services
  • Price (USD)41.49
  • Today's Change-0.31 / -0.74%
  • Shares traded470.06k
  • 1 Year change37.34%
  • Beta--
Data delayed at least 15 minutes, as of Oct 23 2020 21:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Inmode Ltd is an Israel-based company. It designs, develops, manufactures and commercializes energy-based, minimally-invasive surgical aesthetic and medical treatment solutions. The Company’s proprietary technologies are used by physicians to remodel subdermal adipose, or fatty, tissue in a variety of procedures including fat reduction with simultaneous skin tightening, face and body contouring and ablative skin rejuvenation treatments. Its products target a wide array of procedures including simultaneous fat killing and skin tightening, permanent hair reduction, skin appearance and texture, among others. The Company’s products may be used on a variety of body parts, including the face, neck, abdomen, upper arms, thighs and intimate feminine regions. It owns six product platforms: BodyTite, Optimas, Votiva, Contoura, Triton and EmbraceRF. All are market and sell traditionally to plastic and facial surgeons, aesthetic surgeons and dermatologists, among others.

  • Revenue in USD (TTM)158.22m
  • Net income in USD50.25m
  • Incorporated2008
  • Employees251.00
  • Location
    Inmode LtdTavor Building, Sha'ar Yokneam, Pob 533YOKNEAM 2069200IsraelISR
  • Phone+972 49097470
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Lantheus Holdings Inc331.84m11.63m863.90m508.0042.831.6831.502.600.30190.30198.117.720.52265.157.18653,220.501.837.432.048.6747.4048.543.517.561.913.580.30580.001.152.86-21.84--22.08--
BioLife Solutions Inc36.98m3.01m941.50m151.00218.577.12128.5825.460.13280.13281.644.070.44631.769.04244,913.903.63-31.903.88-35.4361.5565.208.13-57.984.72-6.060.00--38.6434.6293.46--31.63--
Orthopediatrics Corp69.65m-21.60m958.50m94.00--3.95--13.76-1.32-1.384.3812.410.29020.41664.66740,904.30-9.00-13.18-10.46-14.8375.5573.66-31.01-19.705.31-3.010.0802--26.0525.09-5.49--29.50--
Luminex Corporation369.12m4.50m989.85m1.25k236.931.9128.852.680.09010.23928.1911.200.55551.946.15296,004.000.70694.050.77514.4557.3663.171.276.425.774.650.281937.365.968.07-190.44---1.02--
Heska Corp141.37m-13.68m1.14bn386.00--4.20--8.04-1.70-1.7018.1028.680.52382.316.85366,243.50-5.055.38-5.556.7043.0143.55-9.646.163.58-0.22240.158---3.756.43-125.04---14.88--
Atrion Corporation154.91m35.15m1.20bn616.0034.595.1325.847.7418.9418.9583.48127.680.60862.097.24251,478.9013.8116.1014.5616.9345.6647.3322.6921.613.65--0.0026.061.721.957.275.7310.0415.84
Nano-X Imaging Ltd0.00-34.67m1.42bn27.00--33.81-----0.7811-0.78110.000.9091------0.00--------------------0.00-------1,081.93------
Pulmonx Corp32.60m-20.70m1.43bn180.00------43.96-0.1041-0.10410.1638--------181,083.30--------68.77---63.52-----9.46----62.94---12.04------
Eargo Inc-100.00bn-100.00bn1.43bn184.00---------------0.2403------------------------0.363--5.44--41.56---30.94------
Inmode Ltd158.22m50.25m1.48bn251.0033.867.2029.209.341.231.233.845.760.92911.8422.85630,350.6029.50--34.95--86.11--31.75--7.81--0.00--56.11--173.32------
Cardiovascular Systems Inc236.55m-27.24m1.57bn779.00--5.77--6.63-0.7882-0.78826.906.770.84772.137.73303,652.10-9.76-8.25-11.56-10.1979.3980.57-11.51-7.715.84-96.850.0719---4.635.44-10,580.78---14.32--
AtriCure Inc.211.98m-50.10m1.71bn730.00--4.09--8.05-1.29-1.295.429.280.40482.068.34290,389.00-9.57-9.38-10.33-10.5672.2372.60-23.63-16.126.81-13.960.1372--14.4716.52-57.86--17.20--
Avanos Medical Inc705.30m-16.90m1.82bn4.70k--1.4474.322.58-0.3549-0.354914.7626.390.39862.035.38150,063.80-0.955-2.78-1.06-3.2855.7655.49-2.40-9.381.951.950.1645--6.94-16.04-270.16---8.41--
Owens & Minor, Inc.8.20bn-11.96m1.88bn6.40k--4.1119.820.2288-0.1973-1.72135.176.202.336.3711.101,280,588.00-0.3401-1.05-0.5477-1.7111.4612.17-0.1459-0.35170.76091.180.7627---2.20-0.490594.28---5.91-60.19
Axonics Modulation Technologies Inc52.76m-82.16m1.97bn302.00--6.62--37.41-2.62-2.621.647.550.21311.236.85174,715.20-33.18---36.27--55.41---155.70--9.91--0.0651--1,854.74---146.08------
Outset Medical Inc28.65m-82.00m2.10bn273.00------73.48-2.00-2.000.6992.88------125,644.70---------57.26---286.25--2.86-31.230.1993--651.27---37.20------
Data as of Oct 23 2020. Currency figures normalised to Inmode Ltd's reporting currency: US Dollar USD

Institutional shareholders

12.23%Per cent of shares held by top holders
HolderShares% Held
Miura Global Management LLCas of 30 Jun 20201.18m3.30%
Gluskin Sheff + Associates, Inc. (Investment Management)as of 30 Jun 2020652.91k1.83%
Fidelity Management & Research Co. LLCas of 30 Jun 2020608.26k1.71%
Nantahala Capital Management LLCas of 30 Jun 2020511.86k1.44%
Susquehanna Financial Group LLLPas of 30 Jun 2020280.65k0.79%
Excellence Investments Ltd.as of 30 Jun 2020258.37k0.73%
RTW Investments LPas of 30 Jun 2020250.00k0.70%
Renaissance Technologies LLCas of 30 Jun 2020234.68k0.66%
Wasatch Advisors, Inc.as of 30 Jun 2020212.79k0.60%
BlackRock Fund Advisorsas of 30 Jun 2020170.71k0.48%
More ▼
Data from 30 Jun 2020 - 30 Jun 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.